Cargando…

Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration

BACKGROUND: Two open-label, randomized, parallel-arm studies compared pharmacokinetics, safety, and tolerability of aripiprazole once-monthly 400 mg following deltoid vs gluteal injection in patients with schizophrenia. METHODS: In the single-dose study, 1 injection of aripiprazole once-monthly 400...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raoufinia, Arash, Peters-Strickland, Timothy, Nylander, Anna-Greta, Baker, Ross A., Eramo, Anna, Jin, Na, Bricmont, Patricia, Repella, Jennifer, McQuade, Robert D., Hertel, Peter, Larsen, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Regular Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5409034/ https://www.ncbi.nlm.nih.gov/pubmed/28204607 http://dx.doi.org/10.1093/ijnp/pyw116

Ejemplares similares

Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study
por: Peters-Strickland, Timothy, et al.
Publicado: (2015)

Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY
por: Potkin, Steven G., et al.
Publicado: (2017)

Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia
por: Kane, John M., et al.
Publicado: (2013)

Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia: Post Hoc Analysis of Positive and Negative Syndrome Scale Marder Factor Scores
por: Ismail, Zahinoor, et al.
Publicado: (2017)

Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis
por: Kane, John M., et al.
Publicado: (2015)

Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate
por: Potkin, Steven G., et al.
Publicado: (2016)

Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole
por: Salzman, Phyllis M, et al.
Publicado: (2017)

Population Pharmacokinetic Modeling and Exposure‐Response Analysis for Aripiprazole Once Monthly in Subjects With Schizophrenia
por: Wang, Xiaofeng, et al.
Publicado: (2022)

Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: A post-hoc analysis of the QUALIFY study
por: Potkin, Steven G., et al.
Publicado: (2017)

Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal(®) Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil
por: Hard, Marjie L., et al.
Publicado: (2019)

PM417. Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning: a post-hoc analysis of QUALIFY, a head-to-head study in schizophrenia
por: Salzman, Phyllis, et al.
Publicado: (2016)

An open-label, positron emission tomography study of the striatal D(2)/D(3) receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participants
por: Wong, Dean F., et al.
Publicado: (2020)

Correction to: An open-label, positron emission tomography study of the striatal D(2)/D(3) receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participants
por: Wong, Dean F., et al.
Publicado: (2021)

Effect of aripiprazole once-monthly 400mg (AOM400) on hospitalisation prevention and use of healthcare resources in schizophrenia patients, a study based on real clinical practice on schizophrenia: AMBITION Study
por: Sanchez-Gistau, V., et al.
Publicado: (2023)

Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data
por: Yan, Tingjian, et al.
Publicado: (2018)

The effect of switching from oral low-dose aripiprazole to aripiprazole once-monthly 300 mg on the quality of life in three patients with schizophrenia
por: Suzuki, Hidenobu, et al.
Publicado: (2017)

Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis
por: De Hert, Marc, et al.
Publicado: (2015)

Acceptance of the Deltoid Muscle Injection of Aripiprazole Long-acting Injectable in the Patients with Schizophrenia
por: Kamei, Hiroyuki, et al.
Publicado: (2020)

Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia
por: Wilson, Michele, et al.
Publicado: (2016)

Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters
por: Shoaf, Susan E., et al.
Publicado: (2021)

Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis
por: Sapin, Christophe, et al.
Publicado: (2016)

Paliperidone Palmitate Long-Acting Injectable Given Intramuscularly in the Deltoid Versus the Gluteal Muscle: Are They Therapeutically Equivalent?
por: Ravenstijn, Paulien, et al.
Publicado: (2016)

The effect of aripiprazole once-monthly on personal and social functioning: post hoc analyses of acute and long-term studies
por: Peters-Strickland, Timothy, et al.
Publicado: (2019)

Discovery research and development history of the dopamine D(2) receptor partial agonists, aripiprazole and brexpiprazole
por: Kikuchi, Tetsuro, et al.
Publicado: (2021)

Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study
por: Calabrese, Joseph R., et al.
Publicado: (2018)

Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection
por: Wang, Sheng-Min, et al.
Publicado: (2014)

Pharmacokinetic and Pharmacodynamic Comparison of Once‐Daily Efavirenz (400 mg vs. 600 mg) in Treatment‐Naïve HIV‐Infected Patients: Results of the ENCORE1 Study
por: Dickinson, L, et al.
Publicado: (2015)

Treatment persistence with aripiprazole once monthly: a 4-year follow-up
por: Fagiolini, Andrea, et al.
Publicado: (2022)

Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
por: Schöttle, Daniel, et al.
Publicado: (2018)

Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
por: Schöttle, Daniel, et al.
Publicado: (2018)

Cerebrospinal-fluid exposure of efavirenz and its major metabolites when dosed at 400 and 600 mg once daily; a randomized controlled trial
por: Winston, Alan, et al.
Publicado: (2014)

Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy
por: Nelson, J. Craig, et al.
Publicado: (2014)

Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder
por: Berman, Robert M, et al.
Publicado: (2011)

Randomized, Double-Blind, Placebo-Controlled Trial Demonstrates the Efficacy and Safety of Oral Aripiprazole for the Treatment of Tourette's Disorder in Children and Adolescents
por: Sallee, Floyd, et al.
Publicado: (2017)

Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies
por: Madera, Jessica J, et al.
Publicado: (2019)

Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
por: Liang, Chih-Sung, et al.
Publicado: (2021)

Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study)
por: Oluboka, Oloruntoba, et al.
Publicado: (2023)

The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies
por: Weiss, Catherine, et al.
Publicado: (2018)

Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study
por: Muzina, D J, et al.
Publicado: (2008)

S233. EVOLUTION OF THE FUNCIONING AND ATTITUDES TO MEDICATION IN A SAMPLE WITH EARLY PSYCHOSIS IN TREATMENT WITH ARIPIPRAZOLE ONCE-MONTHLY
por: Soto, Marta, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lbct93mfl3c6lmhsl4cfckj3sl